Destiny Pharma Ltd   Report issue

For profit Phase 2 Phase 4
Founded: Brighton United Kingdom (1996)
Status: Acquired by Therapix Biosciences Ltd. (2019) → now FSD Pharma (2018)

Organization Overview

First Clinical Trial
2014
NCT02284555
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2019

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Destiny Pharma Plc

Active Ingredients

Drugs in Phase 4 Trials (1)

mupirocin (bactroban) (1 trial)

Drugs in Phase 2 Trials (2)

chlorhexidine (hibitane) (1 trial)

Exeporfinium (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Communicable Diseases (Phase 2)

Infections (Phase 2)

Staphylococcal Infections (Phase 4)

Surgical Wound Infection (Phase 2)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 3
  • # of Trial APIs: 3